Regulatory approval

Published by the Health Service Executive. Approved

Treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation.

This is written in the approval document.

Reimbursement

CDS

Citation

Encorafenib and Binimetinib Therapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6744/563_V3_Encorafenib-and-Binimetinib_Therapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) BRAF p.V600E Melanoma Binimetinib, Encorafenib
HSE (1) BRAF p.V600K Melanoma Binimetinib, Encorafenib